News
Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback